



|                              |           |  |  |  |  |  |      |            |              |         |  |         |   |
|------------------------------|-----------|--|--|--|--|--|------|------------|--------------|---------|--|---------|---|
| Option (Right to Buy) Stock  | \$ 67.46  |  |  |  |  |  | (8)  | 04/01/2020 | Common Stock | 50,000  |  | 50,000  | D |
| Options (Right to buy)       | \$ 177.32 |  |  |  |  |  | (9)  | 08/08/2025 | Common Stock | 60,222  |  | 60,222  | D |
| Stock Options (Right to buy) | \$ 177.32 |  |  |  |  |  | (5)  | 08/08/2025 | Common Stock | 90,334  |  | 90,334  | D |
| Stock Options (Right to buy) | \$ 125.05 |  |  |  |  |  | (4)  | 08/09/2024 | Common Stock | 117,342 |  | 117,342 | D |
| Stock Options (Right to buy) | \$ 125.05 |  |  |  |  |  | (10) | 08/09/2024 | Common Stock | 78,228  |  | 78,228  | D |
| Stock Options (Right to buy) | \$ 94.35  |  |  |  |  |  | (8)  | 08/12/2021 | Common Stock | 66,849  |  | 66,849  | D |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| Kummeth Charles R.<br>425 MARTINGALE ROAD<br>SUITE 2050<br>SCHAUMBURG, IL 60173-2213 | X             |           | Chief Executive Officer |       |

## Signatures

|  |  |                     |
|--|--|---------------------|
| /s/ Brenda S. Furlow, attorney in fact for Charles R. Kummeth pursuant to Power of Attorney previously filed |  | 08/31/2018          |
| <small>**Signature of Reporting Person</small>   |  | <small>Date</small> |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.
- (10) Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- (2) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (3) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (4) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.
- (7) Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
- (8) Fully exercisable
- (9) Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

## POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Brenda S. Furlow, James Hippel, Anna Weispenning, Melodie R. Rose, Andrew Nick, Sarah Tucher or either of them acting alone, the undersigned's true and lawful attorneys-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of October, 2017.

/s/ Charles R. Kummeth